Clinical Trial Update: Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial update on SHR-1314 assessing efficacy, safety, and pharmacokinetics in moderate-to-severe plaque psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis
• Psoriasis Vulgaris

Drugs mentioned

• SHR-1314 (SHR-1314)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Moderate-to-Severe Plaque Psoriasis | Phase 3 | Status: UNKNOWN